S&P 500

5.277,51

0,80%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
MaxCyte Inc (MXCT)
MaxCyte Inc (MXCT) Notícias

MXCT

MaxCyte (MXCT)

MaxCyte Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:MXCT

1 2 3 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
29/05/2024	09:05	GlobeNewswire Inc.	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference	NASDAQ:MXCT	MaxCyte Inc
22/05/2024	09:05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	NASDAQ:MXCT	MaxCyte Inc
07/05/2024	18:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MXCT	MaxCyte Inc
07/05/2024	17:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
07/05/2024	17:05	GlobeNewswire Inc.	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	NASDAQ:MXCT	MaxCyte Inc
10/04/2024	09:05	GlobeNewswire Inc.	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024	NASDAQ:MXCT	MaxCyte Inc
02/04/2024	09:05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)	NASDAQ:MXCT	MaxCyte Inc
12/03/2024	17:05	GlobeNewswire Inc.	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance	NASDAQ:MXCT	MaxCyte Inc
04/03/2024	19:39	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
04/03/2024	18:05	GlobeNewswire Inc.	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	NASDAQ:MXCT	MaxCyte Inc
26/02/2024	18:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MXCT	MaxCyte Inc
14/02/2024	18:26	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MXCT	MaxCyte Inc
14/02/2024	14:25	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MXCT	MaxCyte Inc
09/02/2024	10:05	GlobeNewswire Inc.	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences	NASDAQ:MXCT	MaxCyte Inc
30/01/2024	18:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
30/01/2024	10:05	GlobeNewswire Inc.	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers	NASDAQ:MXCT	MaxCyte Inc
23/01/2024	10:05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	NASDAQ:MXCT	MaxCyte Inc
08/01/2024	18:05	GlobeNewswire Inc.	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:MXCT	MaxCyte Inc
03/01/2024	10:05	GlobeNewswire Inc.	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline	NASDAQ:MXCT	MaxCyte Inc
02/01/2024	04:00	GlobeNewswire Inc.	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director	NASDAQ:MXCT	MaxCyte Inc
11/12/2023	18:05	GlobeNewswire Inc.	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023	NASDAQ:MXCT	MaxCyte Inc
16/11/2023	10:05	GlobeNewswire Inc.	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member	NASDAQ:MXCT	MaxCyte Inc
08/11/2023	18:05	GlobeNewswire Inc.	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance	NASDAQ:MXCT	MaxCyte Inc
06/11/2023	18:05	GlobeNewswire Inc.	MaxCyte to Participate in Two Upcoming Investor Conferences	NASDAQ:MXCT	MaxCyte Inc
04/10/2023	17:05	GlobeNewswire Inc.	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance	NASDAQ:MXCT	MaxCyte Inc
06/09/2023	09:05	GlobeNewswire Inc.	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing	NASDAQ:MXCT	MaxCyte Inc
05/09/2023	09:05	GlobeNewswire Inc.	MaxCyte to Participate in Baird Global Healthcare Conference	NASDAQ:MXCT	MaxCyte Inc
09/08/2023	17:05	GlobeNewswire Inc.	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance	NASDAQ:MXCT	MaxCyte Inc
01/08/2023	09:05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients	NASDAQ:MXCT	MaxCyte Inc
13/07/2023	09:05	GlobeNewswire Inc.	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023	NASDAQ:MXCT	MaxCyte Inc